Sanofi Taps Nestle's Roger as CFO After Swing to Net Loss
By Adria Calatayud
Sanofi named Nestle's Francois-Xavier Roger as its new chief financial officer and reported a swing to a net loss for the fourth quarter despite strong sales of its blockbuster drug Dupixent.
The French pharmaceutical company said Thursday that Roger, who has been CFO at Nestle for more than eight years, will replace Jean-Baptiste Chasseloup de Chatillon, who is stepping down. The change will be effective from April 1.
Net loss for the fourth quarter was 555 million euros ($600.5 million) compared with a profit of EUR3.11 billion for the same period of 2022, Sanofi said. Higher costs and exceptional items hit the company's profitability.
Business operating profit--one of the company's preferred metrics, which strips out exceptional items--fell 5.2% to EUR2.58 billion.
Net sales rose 1.8% to EUR10.92 billion. At constant currency, sales were up 9.3%, with growth in its specialty-care unit driven by continued strength in anti-inflammatory drug Dupixent--jointly developed with Regeneron Pharmaceuticals--and in vaccines.
Analysts expected business operating profit of EUR2.77 billion on sales of EUR11.04 billion, according to estimates provided by the company.
Sanofi reiterated its outlook for 2024.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
February 01, 2024 02:01 ET (07:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks